L. Pullen

发表

VP7 from African horse sickness virus serotype 9 protects mice against a lethal, heterologous serotype challenge.

J. Burroughs, A. Wade-Evans, P. Mertens, 1998, Archives of virology. Supplementum.

Monoclonal antibodies, against O1 serotype foot-and-mouth disease virus, from a natural bovine host, recognize similar antigenic features to those defined by the mouse.

R. Parkhouse, P. Barnett, A. Samuel, 1998, The Journal of general virology.

4-Guanidino-Neu5Ac2en fails to protect chickens from infection with highly pathogenic avian influenza virus.

J. McCauley, C. Penn, M. Forsyth, 1995, Antiviral research.

Mouse protection test as a predictor of the protective capacity of synthetic foot-and-mouth disease vaccines.

R. DiMarchi, G. Mulcahy, C. Gale, 1991, Vaccine.

Development of a mouse model system, coding assignments and identification of the genome segments controlling virulence of African horse sickness virus serotypes 3 and 8.

J. Burroughs, P. Mertens, L. A. Martín, 1998, Archives of virology. Supplementum.

T cell-dependent induction of antibody against foot-and-mouth disease virus in a mouse model.

T. Collen, T. Doel, L. Pullen, 1989, The Journal of general virology.

Temperamental cattle acclimate more substantially to repeated handling

Ronald M. Lewis, W. Swecker, A. Tanner, 2019, Applied Animal Behaviour Science.

Rinderpest and peste des petits ruminants viruses exhibit neurovirulence in mice

T. Barrett, S. McQuaid, S. L. Cosby, 2011, Journal of NeuroVirology.

The immune response against foot-and-mouth disease virus: influence of the T lymphocyte growth factors IL-1 and IL-2 on the murine humoral response in vivo.

K. McCullough, L. Pullen, D. Parkinson, 1992, Immunology letters.

International bank for foot-and-mouth disease vaccine: assessment of Montanide ISA 25 and ISA 206, two commercially available oil adjuvants.

P. Barnett, T. Doel, L. Pullen, 1996, Vaccine.

A protective anti-peptide antibody against the immunodominant site of the A24 Cruzeiro strain of foot-and-mouth disease virus and its reactivity with other subtype viruses containing the same minimum binding sequence.

P. Barnett, T. Doel, R. Butcher, 1996, The Journal of general virology.

Studies on glycoprotein 13 (gp13) of equid herpesvirus 1 using affinity-purified gp13, glycoprotein-specific monoclonal antibodies and synthetic peptides in a hamster model.

R. A. Killington, G. Whittaker, D. Meredith, 1991, The Journal of general virology.

The biological relevance of virus neutralisation sites for virulence and vaccine protection in the guinea pig model of foot-and-mouth disease.

A. Samuel, J. Anderson, C. Dunn, 1998, Virology.

Effect of mutation on the virulence in mice of a strain of foot-and-mouth disease virus.

A. King, K. Saunders, D. Mccahon, 1981, The Journal of general virology.

Chimeric polioviruses that include sequences derived from two independent antigenic sites of foot-and-mouth disease virus (FMDV) induce neutralizing antibodies against FMDV in guinea pigs

G. Belsham, J. Almond, K. Burke, 1991, Journal of virology.

A hamster model of equine herpesvirus type 1 (EHV-1) infection; passive protection by monoclonal antibodies to EHV-1 glycoproteins 13, 14 and 17/18.

G. Allen, P. K. Murray, A. Stokes, 1989, The Journal of general virology.

International bank for foot-and-mouth disease vaccine: stability studies with virus concentrates and vaccines prepared from them.

T. Doel, L. Pullen, 1990, Vaccine.

Guinea pig protection test as indicator of potency of oil emulsion foot-and-mouth disease vaccines.

A. Boge, L. Black, L. Pullen, 1985, Research in veterinary science.

African horsesickness virus VP7 sub-unit vaccine protects mice against a lethal, heterologous serotype challenge.

J. Burroughs, A. Wade-Evans, P. Mertens, 1997, The Journal of general virology.